NCT00191321已完成3 期
TUHRS Study - Teriparatide Use in Hip Replaced Subjects A Pilot Study on the Use of Teriparatide in Severe Osteoporotic Women With Hip Fracture and Submitted to Hip Replacement
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 11
- 主要终点
- Effect of Teriparatide (20 mcg/day for 18 months ) on bone turnover markers: CTx, PINP and BSAP
研究概览
简要总结
A pilot study on the use of Teriparatide in severe osteoporotic women with hip fracture and submitted to hip replacement
The primary objective of this study is to obtain preliminary data, in a pilot group of postmenopausal women with established osteoporosis and a recent hip fracture, who underwent hip replacement 3-6 months before screening phase, about the effect of teriparatide on:
- bone turnover markers: CTx, PINP and BSAP when given at the dose of 20 mcg/day by subcutaneous route for 18 months.
The secondary objectives of the study are as follows:
- Effects of teriparatide on lumbar spine and non-prosthetic femur bone density, as assessed by BMD measurement with dual energy x-ray absorptiometry (DXA)
- Effects of teriparatide on quality of life and back pain during treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 55 Years 至 85 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Ambulatory postmenopausal women with established osteoporosis, based on the disease diagnostic criteria
- •Presence of more than 1 clinical and/or radiological vertebral fractures OR more than 1 non-vertebral fracture
- •Presence of hip fracture with hip replacement surgical procedure (both uncemented or cemented total hip arthroplastics or endoprosthesis) in the 3-6 months before screening phase
- •Age range 55-85 years
- •Normal or clinically insignificant abnormal laboratory values (as determined by the investigator) including serum calcium, PTH(1 84), and 25 hydroxyvitamin D concentrations, and alkaline phosphatase activity.
排除标准
- •History of diseases which affect bone metabolism, other than primary postmenopausal osteoporosis, such as Paget's disease, renal osteodystrophy, osteomalacia, any secondary causes of osteoporosis (included glucocorticoid-induced osteoporosis), hypoparathyroidism, hyperparathyroidism, hyperthyroidism
- •Actual cancer disease or history of malignant neoplasms in the 5 years prior to Visit 2, with the exception of superficial basal cell or squamous cell carcinomas of the skin that have been definitively treated. Subjects with carcinoma in situ of the uterine cervix treated definitively more than 1 year prior to entry into the study may be enrolled.
- •Increased baseline risk of osteosarcoma: Paget's disease of the bone or unexplained elevations of alkaline phosphatase; Prior radiation therapy involving the skeleton
- •Significantly impaired renal function
- •Significantly impaired hepatic function
结局指标
主要结局
Effect of Teriparatide (20 mcg/day for 18 months ) on bone turnover markers: CTx, PINP and BSAP
次要结局
- Effects of teriparatide on lumbar spine and non-prosthetic femur bone density, as assessed by BMD measurement with dual energy x-ray absorptiometry (DXA)
- Effects of teriparatide on quality of life and back pain during treatment.
研究者
研究点 (11)
Loading locations...
相似试验
撤回
3 期
Teriparatide for Fracture Repair in HumansOsteoporosis, Age-RelatedHumeral FracturesNCT02091492Medical University of Vienna
已完成
不适用
Early Effects of Parathyroid Hormone (PTH) on the Proximal FemurOsteoporosisNCT01309399Health Research, Inc.40
进行中（未招募）
不适用
Preoperative Teriparatide Use on Insertional Torque of Pedicle Screws for Lumbar Fusion SurgeryOsteoporosisFusion of Spine, Lumbar RegionNCT03770338The University of Hong Kong192
已完成
2 期
Teriparatide as a Chondroregenerative Therapy in OACartilage DegenerationKnee OsteoarthritisNCT03072147Christopher Ritchlin76
终止
2 期
Teriparatide for Postsurgical HypoparathyroidismHypoparathyroidism Post-surgicalNCT01171690Mayo Clinic5